8-K: MannKind Completes scPharmaceuticals Acquisition, Details CVRs

MannKind Corporation has finalized its acquisition of scPharmaceuticals Inc. for approximately $296.5 million in cash and contingent value rights, funded by existing cash and a new $250 million delayed draw term loan.

Summary

• MannKind Corporation completed the acquisition of scPharmaceuticals Inc. on October 7, 2025, through a tender offer and subsequent merger, making scPharmaceuticals a wholly-owned subsidiary.
• The offer price for scPharma shares was $5.35 in cash plus one non-tradable Contingent Value Right (CVR) per share, with a maximum potential CVR payment of $1.00 per CVR.
• As of the October 6, 2025 expiration date, 39,933,692 scPharma shares (approximately 73.47%) were validly tendered, with an additional 5,930,025 shares (approximately 10.91%) under guaranteed delivery.
• The total cash acquisition price paid by MannKind and Purchaser at closing was approximately $296.5 million.
• MannKind funded the acquisition and the extinguishment of scPharma's existing debt using available cash on hand and $250.0 million from a new delayed draw term loan.
• The CVRs entitle holders to contingent cash payments upon the achievement of two milestones: FDA approval of an Injection Product (Milestone 1) and achievement of specific worldwide net sales targets for Products (Milestone 2).
• Milestone 1 payments range from $0.75 per CVR (if achieved by September 30, 2026) to $0.25 per CVR (if achieved by June 30, 2027), with no payment if approval occurs after June 30, 2027.
• Milestone 2 payments range from $0.10 to $0.25 per CVR, based on achieving worldwide net sales between $110.0 million and $120.0 million in any trailing 12-month period ending by December 31, 2026, with no payment if sales are less than $110.0 million.
• MannKind is obligated to use "Commercially Reasonable Efforts" to achieve these CVR milestones.
• The $250.0 million delayed draw term loan was borrowed under the Blackstone Credit Facility, which matures on August 6, 2030, and bears interest at Term SOFR (subject to a 2% floor) plus a margin of 4.75% (increasing to 5.00% if the debt-to-adjusted EBITDA ratio is >= 5.00:1.00).
• MannKind also repaid and extinguished scPharma's outstanding indebtedness under the Existing Perceptive Credit Agreement and repurchased Perceptive's revenue participation rights, totaling approximately $82.6 million.
• Financial statements of the acquired business and unaudited pro forma condensed combined financial information will be filed by amendment to this Current Report on Form 8-K not later than 71 calendar days after the filing date.

Sentiment

Score: 7

Explanation: The completion of the acquisition is a positive strategic step, expanding MannKind's product portfolio and pipeline. The CVR structure is a prudent way to manage acquisition costs and align incentives. However, the significant debt incurred and the inherent uncertainty of CVR milestone achievement introduce financial and operational risks that warrant a moderately positive but cautious sentiment.

Positives

• Successful completion of the scPharmaceuticals acquisition, expanding MannKind's product portfolio and strategic market position.
• The CVR structure aligns incentives with future product performance and defers a portion of the acquisition cost, linking it to the achievement of specific regulatory and commercial milestones.
• Secured $250.0 million in delayed draw term loans from Blackstone, providing necessary capital to fund the acquisition and extinguish scPharma's existing debt.
• MannKind is contractually obligated to use "Commercially Reasonable Efforts" to achieve the CVR milestones, indicating a commitment to the acquired assets' development and commercialization.

Negatives

• Significant cash outlay of approximately $296.5 million for the acquisition and an additional $82.6 million for scPharma's debt extinguishment, totaling $379.1 million.
• Increased debt burden for MannKind with the new $250.0 million term loan, potentially impacting the company's financial leverage and flexibility.
• The interest rate on the new loan (SOFR + 4.75% with a 2% floor) represents a substantial ongoing financial cost.
• The interest rate margin increases to 5.00% if MannKind's debt-to-adjusted EBITDA ratio is greater than or equal to 5.00:1.00, indicating potential for higher interest expenses if financial performance does not meet expectations.
• There is "no assurance" that either CVR Milestone 1 or Milestone 2 will be achieved, meaning the full potential CVR payment of up to $1.00 per CVR might not be realized by former scPharma shareholders.

Risks

• Failure to achieve CVR Milestone 1 (FDA approval of Injection Product) by June 30, 2027, which would result in no payment for that milestone.
• Failure to achieve CVR Milestone 2 (at least $110.0 million worldwide net sales of Products) by December 31, 2026, which would result in no payment for that milestone.
• The CVRs are non-transferable (subject to limited exceptions), which restricts liquidity for holders.
• Increased financial leverage due to the $250.0 million delayed draw term loan, potentially impacting MannKind's credit profile and future borrowing capacity.
• Potential for higher interest expenses if MannKind's debt-to-adjusted EBITDA ratio exceeds 5.00:1.00.
• Integration risks associated with combining scPharmaceuticals Inc. into MannKind's existing operations.
• Regulatory risks related to obtaining FDA approval for the Injection Product (SCP-111).
• Market acceptance and sales performance risks for the acquired Products (Injection Products and FUROSCIX Infusors).

Future Outlook

MannKind will focus on integrating scPharmaceuticals and advancing the Injection Product towards FDA approval and commercialization to achieve the CVR milestones. The company is committed to using commercially reasonable efforts to achieve these milestones, though there is no guarantee of their attainment by the specified outside dates.

Industry Context

The acquisition of scPharmaceuticals by MannKind represents a strategic move to expand its product pipeline, particularly in drug-device combination products, a growing segment within the pharmaceutical industry. This type of M&A activity is common as companies seek to diversify revenue streams and leverage existing commercial infrastructure. The use of a Contingent Value Right (CVR) structure is a prevalent mechanism in biotech and pharmaceutical M&A, designed to bridge valuation gaps and share future development and commercialization risks and rewards between the acquirer and the target's former shareholders.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) is a standard practice in pharmaceutical and biotech M&A, particularly for assets with significant regulatory or commercialization hurdles. For example, Sanofi utilized CVRs in its acquisition of Principia Biopharma, tying additional payments to clinical trial and regulatory milestones for its BTK inhibitor program.
• Bristol Myers Squibb also used CVRs in its acquisition of Celgene, with payments contingent on the FDA approval of specific drug candidates (e.g., ozanimod, liso-cel, bb2121).
• The interest rate structure for the Blackstone Credit Facility (SOFR + 4.75% with a 2% floor) is within the typical range for leveraged financing in the biotech sector, reflecting the risk profile of growth-oriented companies that may not yet have consistent profitability.
• The contractual obligation for "Commercially Reasonable Efforts" to achieve milestones is a standard clause in CVR agreements, aiming to ensure the acquirer actively pursues the development and commercialization of the underlying assets, similar to agreements seen in numerous other biotech acquisitions.

Stakeholder Impact

• Shareholders (MannKind): Potential for long-term value creation through an expanded product portfolio and future revenue streams from acquired assets, but also increased debt and the inherent risks associated with CVR milestone achievement.
• Shareholders (scPharmaceuticals): Received immediate cash consideration of $5.35 per share plus CVRs, providing both liquidity and potential future upside tied to the performance of the acquired products.
• Employees (scPharmaceuticals): Integration into MannKind, with scPharma continuing as a wholly-owned subsidiary. Equity award holders received cash and CVRs in exchange for their awards.
• Creditors (MannKind): New financial obligation of $250.0 million under the Blackstone Credit Facility, increasing the company's overall debt burden.
• Creditors (scPharmaceuticals): Existing debt of approximately $82.6 million under the Perceptive Credit Agreement and Revenue Participation Right Purchase and Sale Agreement was repaid and extinguished.

Next Steps

• MannKind will proceed with the integration of scPharmaceuticals Inc. into its operations as a wholly-owned subsidiary.
• The company will continue to pursue U.S. Food and Drug Administration (FDA) approval for the Injection Product (SCP-111) to achieve CVR Milestone 1.
• MannKind will work towards achieving worldwide net sales of at least $110.0 million for all Injection Products and FUROSCIX Infusors by December 31, 2026, to achieve CVR Milestone 2.
• MannKind will file the required financial statements of the acquired business and unaudited pro forma condensed combined financial information by amendment within 71 calendar days.

Key Dates

Recommendation

The acquisition of scPharmaceuticals is a significant strategic move for MannKind, offering growth potential through new products and pipeline assets. The CVR structure is a reasonable approach to manage acquisition costs and align incentives. However, the immediate increase in debt and the inherent uncertainties surrounding the achievement of CVR milestones (regulatory approval and sales targets) warrant a cautious approach. Investors should monitor the integration process, progress towards CVR milestones, and the company's financial leverage before making a more aggressive investment decision.

Keywords

MannKind, scPharmaceuticals, acquisition, merger, tender offer, CVR, contingent value rights, FDA approval, SCP-111, FUROSCIX, net sales, Blackstone, credit facility, debt, pharmaceutical, biotech, drug-device combination